Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Fisman

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Peerj|June 4, 2024
Public transit mobility as a leading indicator of COVID-19 transmission in 40 cities during the first wave of the pandemicJean-Paul R Soucy, Shelby L Sturrock, Isha Berry, et al.
Critical Care (London, England)|January 25, 2013
Critical care resource allocation: trying to PREEDICCT outcomes without a crystal ballMichael D Christian, Robert Fowler, Matthew P Muller, et al.
Human Vaccines & Immunotherapeutics|June 5, 2024
The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analysesDavid Fisman, Norberto Giglio, Myron J Levin, et al.
Plos One|April 22, 2026
Healthcare resource utilization and cost burden of COVID-19 according to vaccination status in adults in Ontario, Canada, 2021-2023Chloe McDonald, Ana Gabriela Grajales, Nassim Ait Yahia, et al.
The Journal of Infectious Diseases|August 24, 2017
A Platform for Monitoring Regional Antimicrobial Resistance, Using Online Data Sources: ResistanceOpenDerek R MacFadden, David Fisman, Jeff Andre, et al.
Microbiology Spectrum|February 24, 2022
Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple AssaysAshleigh R Tuite, David Fisman, Kento T Abe, et al.
Vaccine|July 21, 2010
Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian ExperienceBeate Sander, Chris T Bauch, David Fisman, et al.
Science (New York, N.Y.)|May 27, 2003
Transmission dynamics and control of severe acute respiratory syndromeMarc Lipsitch, Ted Cohen, Ben Cooper, et al.
Antimicrobial Agents and Chemotherapy|March 11, 2020
Using Genetic Distance from Archived Samples for the Prediction of Antibiotic Resistance in <i>Escherichia coli</i>Derek R MacFadden, Bryan Coburn, Karel Břinda, et al.
Clinical Microbiology Reviews|May 22, 2024
Masks and respirators for prevention of respiratory infections: a state of the science reviewTrisha Greenhalgh, C Raina MacIntyre, Michael G Baker, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Peerj|June 4, 2024
Public transit mobility as a leading indicator of COVID-19 transmission in 40 cities during the first wave of the pandemicJean-Paul R Soucy, Shelby L Sturrock, Isha Berry, et al.
Critical Care (London, England)|January 25, 2013
Critical care resource allocation: trying to PREEDICCT outcomes without a crystal ballMichael D Christian, Robert Fowler, Matthew P Muller, et al.
Human Vaccines & Immunotherapeutics|June 5, 2024
The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analysesDavid Fisman, Norberto Giglio, Myron J Levin, et al.
Plos One|April 22, 2026
Healthcare resource utilization and cost burden of COVID-19 according to vaccination status in adults in Ontario, Canada, 2021-2023Chloe McDonald, Ana Gabriela Grajales, Nassim Ait Yahia, et al.
The Journal of Infectious Diseases|August 24, 2017
A Platform for Monitoring Regional Antimicrobial Resistance, Using Online Data Sources: ResistanceOpenDerek R MacFadden, David Fisman, Jeff Andre, et al.
Microbiology Spectrum|February 24, 2022
Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple AssaysAshleigh R Tuite, David Fisman, Kento T Abe, et al.
Vaccine|July 21, 2010
Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian ExperienceBeate Sander, Chris T Bauch, David Fisman, et al.
Science (New York, N.Y.)|May 27, 2003
Transmission dynamics and control of severe acute respiratory syndromeMarc Lipsitch, Ted Cohen, Ben Cooper, et al.
Antimicrobial Agents and Chemotherapy|March 11, 2020
Using Genetic Distance from Archived Samples for the Prediction of Antibiotic Resistance in <i>Escherichia coli</i>Derek R MacFadden, Bryan Coburn, Karel Břinda, et al.
Clinical Microbiology Reviews|May 22, 2024
Masks and respirators for prevention of respiratory infections: a state of the science reviewTrisha Greenhalgh, C Raina MacIntyre, Michael G Baker, et al.
Pageof 7